These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25339357)

  • 1. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
    Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
    Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
    Zhang Y; Lin CHS; Kaushansky K; Zhan H
    Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms.
    Zhang H; Kafeiti N; Masarik K; Lee S; Yang X; Zheng H; Zhan H
    Arterioscler Thromb Vasc Biol; 2024 Sep; 44(9):1960-1974. PubMed ID: 38989576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.
    Spivak JL; Merchant A; Williams DM; Rogers O; Zhao W; Duffield A; Resar LS; Moliterno AR; Zhao ZJ
    PLoS One; 2020; 15(6):e0232801. PubMed ID: 32479500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.
    Zhan H; Lin CHS; Segal Y; Kaushansky K
    Leukemia; 2018 Feb; 32(2):462-469. PubMed ID: 28744010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease.
    Behrens K; Kauppi M; Viney EM; Kueh AJ; Hyland CD; Willson TA; Salleh L; de Graaf CA; Babon JJ; Herold MJ; Nicola NA; Alexander WS
    Leukemia; 2024 Jun; 38(6):1342-1352. PubMed ID: 38491305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
    Kaushansky K; Zhan H
    Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2
    Lin CH; Kaushansky K; Zhan H
    Blood Cells Mol Dis; 2016 Nov; 62():42-48. PubMed ID: 27865175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
    Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
    Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
    Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H
    Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.
    Cabagnols X; Favale F; Pasquier F; Messaoudi K; Defour JP; Ianotto JC; Marzac C; Le Couédic JP; Droin N; Chachoua I; Favier R; Diop MK; Ugo V; Casadevall N; Debili N; Raslova H; Bellanné-Chantelot C; Constantinescu SN; Bluteau O; Plo I; Vainchenker W
    Blood; 2016 Jan; 127(3):333-42. PubMed ID: 26450985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N
    Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.
    Zhao B; Mei Y; Cao L; Zhang J; Sumagin R; Yang J; Gao J; Schipma MJ; Wang Y; Thorsheim C; Zhao L; Stalker T; Stein B; Wen QJ; Crispino JD; Abrams CS; Ji P
    J Clin Invest; 2018 Jan; 128(1):125-140. PubMed ID: 29202466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
    Zhan H; Kaushansky K
    Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.
    Bersenev A; Wu C; Balcerek J; Tong W
    J Clin Invest; 2008 Aug; 118(8):2832-44. PubMed ID: 18618018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.
    Tefferi A; Noel P; Hanson CA
    J Mol Diagn; 2011 Sep; 13(5):461-6. PubMed ID: 21723416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.